Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines (BPMC) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Kate Haviland will deliver a corporate overview and present the company's 2025 outlook on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
The presentation will be accessible through a live webcast on the Investors & Media section of Blueprint Medicines' website. Interested parties can access the replay, which will remain available on the company's website for 30 days after the presentation.
Blueprint Medicines (BPMC) ha annunciato la sua prossima partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Il CEO Kate Haviland presenterà una panoramica aziendale e fornirà le prospettive per il 2025 lunedì 13 gennaio 2025, alle 9:00 PT (12:00 ET).
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Investitori e Media del sito web di Blueprint Medicines. Le parti interessate possono accedere alla registrazione, che rimarrà disponibile sul sito dell'azienda per 30 giorni dopo la presentazione.
Blueprint Medicines (BPMC) ha anunciado su próxima participación en la 43ª Conferencia Anual de Salud de J.P. Morgan. La directora ejecutiva Kate Haviland ofrecerá una visión general de la empresa y presentará las perspectivas para 2025 el lunes 13 de enero de 2025, a las 9:00 a.m. PT (12:00 p.m. ET).
La presentación estará disponible a través de una transmisión web en vivo en la sección de Inversores y Medios del sitio web de Blueprint Medicines. Las partes interesadas pueden acceder a la repetición, que estará disponible en el sitio de la empresa durante 30 días después de la presentación.
블루프린트 메디슨스 (BPMC)는 제43회 연례 J.P. 모건 헬스케어 콘퍼런스에 참석할 예정이라고 발표했습니다. CEO인 케이트 하빌랜드가 기업 개요를 발표하고 2025년의 전망을 2025년 1월 13일 월요일 오전 9:00 PT (오후 12:00 ET)에 소개할 예정입니다.
프레젠테이션은 블루프린트 메디슨스 웹사이트의 투자자 및 미디어 섹션을 통해 실시간으로 시청할 수 있습니다. 관심 있는 분들은 발표 후 30일 동안 회사 웹사이트에서 재생 영상을 확인할 수 있습니다.
Blueprint Medicines (BPMC) a annoncé sa prochaine participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La PDG Kate Haviland présentera un aperçu de l'entreprise et les perspectives pour 2025 le lundi 13 janvier 2025 à 9h00 PT (12h00 ET).
La présentation sera accessible via un webinaire en direct dans la section Investisseurs et Médias du site web de Blueprint Medicines. Les parties intéressées pourront accéder à la rediffusion, qui sera disponible sur le site de l'entreprise pendant 30 jours après la présentation.
Blueprint Medicines (BPMC) hat seine bevorstehende Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. CEO Kate Haviland wird einen Unternehmensüberblick geben und die Aussichten für 2025 am Montag, den 13. Januar 2025, um 9:00 Uhr PT (12:00 Uhr ET) präsentieren.
Die Präsentation wird über ein Live-Streaming auf der Investor- und Medienseite der Website von Blueprint Medicines zugänglich sein. Interessierte Parteien können die Aufzeichnung abrufen, die 30 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar ist.
- None.
- None.
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the
Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334060.html
SOURCE Blueprint Medicines Corporation
FAQ
When is Blueprint Medicines (BPMC) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Blueprint Medicines' J.P. Morgan Healthcare Conference presentation?
How long will the BPMC J.P. Morgan Conference presentation replay be available?
What topics will Blueprint Medicines cover at the 2025 J.P. Morgan Healthcare Conference?
